Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cryo Cell International (CCEL) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Cryo Cell International (CCEL) over the last 16 years, with Q3 2025 value amounting to $59.6 million.

  • Cryo Cell International's Current Deferred Revenue rose 828.57% to $59.6 million in Q3 2025 from the same period last year, while for Aug 2025 it was $59.6 million, marking a year-over-year increase of 828.57%. This contributed to the annual value of $56.3 million for FY2024, which is 1071.74% up from last year.
  • Cryo Cell International's Current Deferred Revenue amounted to $59.6 million in Q3 2025, which was up 828.57% from $58.4 million recorded in Q2 2025.
  • Over the past 5 years, Cryo Cell International's Current Deferred Revenue peaked at $59.6 million during Q3 2025, and registered a low of $36.8 million during Q1 2021.
  • Over the past 5 years, Cryo Cell International's median Current Deferred Revenue value was $48.1 million (recorded in 2023), while the average stood at $48.2 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first soared by 32776.35% in 2021, then surged by 828.57% in 2025.
  • Cryo Cell International's Current Deferred Revenue (Quarter) stood at $40.6 million in 2021, then increased by 12.19% to $45.6 million in 2022, then increased by 11.64% to $50.9 million in 2023, then rose by 10.72% to $56.3 million in 2024, then increased by 5.75% to $59.6 million in 2025.
  • Its last three reported values are $59.6 million in Q3 2025, $58.4 million for Q2 2025, and $57.2 million during Q1 2025.